Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Graefe-Mody EU, Brand T, Ring A, Withopf B, Stangier J, Iovino M, Woerle HJ.

Int J Clin Pharmacol Ther. 2011 May;49(5):300-10.

PMID:
21543033
2.

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.

Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K.

Drug Metab Dispos. 2010 Apr;38(4):667-78. doi: 10.1124/dmd.109.031476. Epub 2010 Jan 19.

PMID:
20086031
3.

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats.

Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, Fuchs H.

Biopharm Drug Dispos. 2009 Nov;30(8):422-36. doi: 10.1002/bdd.676.

PMID:
19771584
4.

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA.

Curr Med Res Opin. 2009 Aug;25(8):1963-72. doi: 10.1185/03007990903094361.

PMID:
19552619
5.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers.

Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA.

J Clin Pharmacol. 2008 Oct;48(10):1171-8. doi: 10.1177/0091270008323753.

PMID:
18812608

Supplemental Content

Loading ...
Support Center